IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab

Human Antibodies

Volumn 19, Issue 4, 2010, Pages 89-99

  Patel, Dipa ^a   Guo, Xuemei ^a   Ng, Stanley ^a   Melchior, Maxine ^a   Balderes, Paul ^a   Burtrum, Douglas ^a   Persaud, Kris ^a   Luna, Xenia ^a   Ludwig, Dale L ^a   Kang, Xiaoqiang ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

antibody dependent cellular cytotoxicity; cetuximab; Epidermal growth factor receptor; monoclonal antibody; panitumumab

Indexed keywords

AGLYCOSYLATED CORN CETUXIMAB; CD16 ANTIGEN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FC RECEPTOR; GLYCOSYLATED CORN CETUXIMAB; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; LACTATE DEHYDROGENASE; PANITUMUMAB; UNCLASSIFIED DRUG;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CELL STRAIN HCT116; CELL STRAIN HT29; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG RECEPTOR BINDING; ENZYME RELEASE; EVALUATION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN INDUCTION; RECEPTOR AFFINITY;

ANTIBODIES, MONOCLONAL; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; KILLER CELLS, NATURAL; L-LACTATE DEHYDROGENASE; LEUKOCYTES, MONONUCLEAR; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 78650597089     PISSN: 10932607     EISSN: None     Source Type: Journal    
DOI: 10.3233/HAB-2010-0232     Document Type: Article

References (30)

1. J.B. Vermorken, R. Mesia, F. Rivera et al., Platinum-based chemotherapy plus cetuximab in head and neck cancer, N Engl J Med 359 (2008), 1116-1127.
2. R. Pirker, J.R. Pereira, A. Szczesna et al., Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet 373 (2009), 1525-1531.
3. J.A. Bonner, P.M. Harari, J. Giralt et al., Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck, N Engl J Med 354 (2006), 567-78.
4. E. Van Cutsem, P. Rougier, C. Kohne et al., A metaanalysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1stline treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status, Eur J Cancer 7(Suppl) (2009), 345.
5. D.J. Jonker, C.J.O'Callaghan, C.S.Karapetis et al., Cetuximab for the treatment of colorectal cancer, N Engl J Med 357 (2007), 2040-2048.
6. C.S. Karapetis, S. KhambataFord, D.J. Jonker et al., Kras mutations and benefit from cetuximab in advanced colorectal cancer, N Engl J Med 359 (2008), 1757-1765.
7. R. Clynes, Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity, Hematol Oncol Clin N Am 20 (2006), 585-612.
8. A. Iannello and A. Ahmad, Role of antibody-dependent cellmediated cytotoxicity in he efficacy of therapeutic anticancer monoclonal antibodies, Cancer Metastasis Rev 24 (2005), 487-499.
9. Y. Kawaguchi, K. Kono, K. Mimura et al., Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma, Int J Cancer 120 (2006), 781-787. (Pubitemid 46175397)
10. J. Kurai, H. Chikumi, K. Hashimoto et al., Antibodydependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines, Clin Cancer Res 13 (2007), 1552-1561.
11. S.Krapp, Y.Mimura, R. Jefferis, R.Huber and P. Sondermann, Structural analysis of human IgGFc glycoforms reveals a correlation between glycosylation and structural integrity, J Mol Biol 325 (2003), 979-989.
12. R. Jefferis, Antibody therapeutics: isotype and glycoform selection, Expert Opin Biol Ther 7 (2007), 1401-1413.
13. M. Peeters, J. Balfour and D. Arnold, Review article: panitumumab - a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer, Aliment Pharmacol Ther 28 (2008), 269-281.
14. K.Y. Chung, J. Shia, N.E. Kemeny et al., Cetuximab shows the activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry, J Clin Oncol 23 (2005), 1803-1810.
15. D. Patel, P.Balderes, A. Lahiji et al., Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1, Hum Antibodies 16 (2007), 127-136.
16. C. Stroh, J. Reusch, J. Schmidt, J. Splittgerber and A Blaukat, Pharmacological and immunological characterization of the therapeutic anti-EGFR antibodies cetuximab, panitumumab and matuzumab: The combination of cetuximab and matuzumab results in enhanced effector functions, ASCO (2010), Abstract No. LB316.
17. P. Bruhns, B. Iannascoli, P. England et al., Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses, Blood 113 (2009), 3716-3725.
18. N. Sethuraman and T.A. Stadheim, Challenges in therapeutic glycoprotein production, Curr Opin Biotechnol 17 (2006), 341-346.
19. S.A. Brooks, Protein glycosylation in diverse cell systems: implications formodification and analysis of recombinant proteins, Expert Rev Proteomics 3 (2006), 345-359.
20. M. Keaney, S. McPhail, C.A. Jodouin and M. Richter, The antibody-dependent cellmediated cytotoxic reaction. II. The effect of the concentration of anti-target cell antibodies on the identity of the human effector cells, Immunology 40 (1980), 205-210.
21. M.P. Velders, C.M. van Rhijn, E. Oskam, G.J. Fleuren, S.O. Warnaar and S.V. Litvinov, The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinoma, Br J Cancer 78 (1998), 478-483.
22. Z. Fan, H.Masui, I. Altas and J.Mendelsohn, Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies, Cancer Res 53 (1993), 4322-4328.
23. W. Zhang, W. Zhang, M. Gordon, A.M. Schultheis et al., FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab, J Clin Oncol 25 (2007), 3712-3718.
24. F. Bibeau, E. LopezCrapez, F. Di Fiore et al., Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan, J Clin Oncol0 27, 1122-1129.
25. J. Pander, H. Gelderblom, N.F. Antonini et al., Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wildtype metastatic colorectal cancer, Eur J Cancer (2010); doi:10.1016/j.ejca.2010.03. 017.
26. G. Cartron, L. Dacheux, G. Salles et al., Therapeutic activity of humanized antiCD20 monoclonal antibody and polymorphism in IgG Fc receptor FcRIIIa gene, Blood 99 (2002), 754-758.
27. W.K. Weng and R. Levy, Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma, J Clin Oncol 21 (2003), 3940-3947.
28. J.Wu, J.C. Edberg, P.B. Redecha et al., A novel polymorphism of FcRIIIa (CD16) alters receptor function and predisposes to autoimmune disease, J Clin Invest 100 (1997), 1059-1070.
29. P.W. Parren, P.A. Warmerdam, L.C. Boeije et al., On the interaction of the IgG subclasses with the low affinity FcRIIa (CD32) on humanmonocytes, neutrophils, and platelets.Analysis of a functional polymorphism to human IgG2, J Clin Invest 90 (1992), 1537-1546.
30. R.A. Clynes, T.L. Towers, L.G. Presta and J.V. Ravetch, Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nature Med 6 (2000), 443-446.